Adamas Pharmaceuticals Inc. (NASDAQ:ADMS)’s share price fell 2.9% during trading on Friday . The company traded as low as $14.49 and last traded at $14.64, with a volume of 191,787 shares traded. The stock had previously closed at $15.07.

A number of brokerages recently commented on ADMS. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday. Cowen and Company reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Thursday, May 12th. Mizuho upgraded Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating in a research report on Monday, June 13th. JMP Securities reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $44.00 price objective on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $32.00.

The firm’s market cap is $323.67 million. The company’s 50 day moving average price is $14.22 and its 200-day moving average price is $15.29.

A hedge fund recently bought a new stake in Adamas Pharmaceuticals stock. Ameriprise Financial Inc. bought a new stake in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 64,978 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,840,000. Ameriprise Financial Inc. owned 0.35% of Adamas Pharmaceuticals at the end of the most recent quarter.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.